More recently, a proof of concept trial investigating crenolanib monotherapy (NCT02626364) in patients with recurrent/refractory GBM included patients with PDGFRA gene amplification, as determined by FISH, at the time of diagnosis or time of recurrence [97]. Here, PDGFRA is linked to glioblastoma.